Diagnostics firm Sera Prognostics reports a significant Q1 2026 revenue decline amid lower-than-expected test volumes and pricing pressure.
Sera Prognostics posted a steep revenue decline in Q1 2026, driven by weaker demand for its prenatal diagnostic tests. The company cited lower test volumes and pricing adjustments as key factors behind the drop.
Analysts had anticipated a modest revenue contraction, but the actual decline exceeded expectations. Comparable revenue in Q1 2025 had shown growth, highlighting a sharp reversal in performance.
Shares of Sera Prognostics fell in after-hours trading following the earnings call disclosure.